SCHEMBL9949115

SCHEMBL9949115

CC(C)(C)OC(=O)N1CCNC(=O)C12CCN(Cc1ccccc1)CC2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 5/20 0.50
OPRD1 P41143 5/20 0.50
OPRK1 P41145 5/20 0.50
OPRM1 P35372 4/20 0.50
CCR5 P51681 6/20 0.47
NPFFR1 Q9GZQ6 1/20 0.45
NPFFR2 Q9Y5X5 1/20 0.45
CYP2D6 P10635 3/20 0.43
ALDH1A1 P00352 3/20 0.42
CYP3A4 P08684 2/20 0.42
CACNA1F O60840 1/20 0.42
CHRM2 P08172 1/20 0.42
ADRB1 P08588 1/20 0.42
DRD2 P14416 1/20 0.42
SLC6A2 P23975 1/20 0.42
ADRA1D P25100 1/20 0.42
ADRA1A P35348 1/20 0.42
HRH1 P35367 1/20 0.42
ADRA1B P35368 1/20 0.42
DRD3 P35462 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9949023 0.84 OPRL1 (0.58) OPRL1OPRD1OPRK1OPRM1CCR5
SCHEMBL17760277 0.82 CCR5 (0.49) OPRD1OPRK1OPRM1CCR5SLC6A3
SCHEMBL23041367 0.81 OPRK1 (0.52) OPRD1OPRK1CCR5SLC6A3MAPK1
SCHEMBL9948870 0.78 GRIN2B (0.40) CCR5USP2MAPK1HSD17B10
SCHEMBL31401367 0.78 GRIN2B (0.41) CCR5USP2MAPK1
SCHEMBL25590864 0.78 NPFFR1 (0.49) OPRL1OPRD1OPRK1NPFFR1NPFFR2
SCHEMBL8248950 0.77 NPFFR1 (0.48) OPRL1OPRD1OPRK1NPFFR1NPFFR2
SCHEMBL3407611 0.75 NPFFR1 (0.46) OPRL1OPRD1OPRK1OPRM1CCR5
SCHEMBL19839907 0.75 OPRD1 (0.46) OPRD1OPRK1CCR5MAPK1KMT2A
SCHEMBL6613639 0.75 OPRL1 (0.46) OPRL1OPRD1OPRK1OPRM1CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012101487-A1 DI/TRI-AZA-SPIRO-C9-C11ALKANES NOVARTIS AG (CH) 2012-08-02 WO disclosed
WO-2012101487-A1 DI/TRI-AZA-SPIRO-C9-C11ALKANES NOVARTIS AG (CH) 2012-08-02 WO disclosed
US-20120165331-A1 Di/tri-aza-spiro-C9-C11alkanes AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-06-28 US disclosed
US-20120165331-A1 Di/tri-aza-spiro-C9-C11alkanes AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-06-28 US disclosed
US-20120165331-A1 Di/tri-aza-spiro-C9-C11alkanes AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165331-A1 Di/tri-aza-spiro-C9-C11alkanes TACR2, TACR1, AGTR1 OPRL1 759/4885OPRD1 162/4885OPRK1 222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.